Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets

Abstract Background: For patients with type 2 diabetes, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) currently recommend a glycosylated hemoglobin (HbA1c ) target of

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2008-03, Vol.30 (3), p.552-554
Main Author: Moses, Robert G., MD
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biomarkers - blood
Carbamates - therapeutic use
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes. Impaired glucose tolerance
Drug Therapy, Combination
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Glycated Hemoglobin A - drug effects
glycosylated hemoglobin
HbA 1c
Humans
Hypoglycemic Agents - therapeutic use
Internal Medicine
Medical Education
Medical sciences
metformin
Metformin - therapeutic use
Pharmacology. Drug treatments
Piperidines - therapeutic use
Randomized Controlled Trials as Topic - statistics & numerical data
repaglinide
Treatment Outcome
type 2 diabetes
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background: For patients with type 2 diabetes, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) currently recommend a glycosylated hemoglobin (HbA1c ) target of
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2008.03.007